Janku, F.; Choong, G.M.; Opyrchal, M.; Dowlati, A.; Hierro, C.; Rodon, J.; Wicki, A.; Forster, M.D.; Blagden, S.P.; Yin, J.;
et al. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers 2024, 16, 1137.
https://doi.org/10.3390/cancers16061137
AMA Style
Janku F, Choong GM, Opyrchal M, Dowlati A, Hierro C, Rodon J, Wicki A, Forster MD, Blagden SP, Yin J,
et al. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers. 2024; 16(6):1137.
https://doi.org/10.3390/cancers16061137
Chicago/Turabian Style
Janku, Filip, Grace M. Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Jordi Rodon, Andreas Wicki, Martin D. Forster, Sarah P. Blagden, Jun Yin,
and et al. 2024. "A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors" Cancers 16, no. 6: 1137.
https://doi.org/10.3390/cancers16061137
APA Style
Janku, F., Choong, G. M., Opyrchal, M., Dowlati, A., Hierro, C., Rodon, J., Wicki, A., Forster, M. D., Blagden, S. P., Yin, J., Reid, J. M., Muller, H., Cmiljanovic, N., Cmiljanovic, V., & Adjei, A. A.
(2024). A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers, 16(6), 1137.
https://doi.org/10.3390/cancers16061137